Erin Wilson
Stock Analyst at Morgan Stanley
(1.81)
# 3,037
Out of 4,711 analysts
19
Total ratings
46.15%
Success rate
0.75%
Average return
Main Sectors:
Stocks Rated by Erin Wilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPD Rapid7 | Maintains: Equal-Weight | $46 | $39.36 | +16.87% | 4 | Jul 10, 2024 | |
| ALGN Align Technology | Maintains: Outperform | $715 → $732 | $211.06 | +246.82% | 3 | Jul 29, 2021 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $352 → $385 | $185.77 | +107.25% | 1 | Jul 20, 2021 | |
| IQV IQVIA Holdings | Maintains: Outperform | $242 → $265 | $197.27 | +34.33% | 1 | Jul 20, 2021 | |
| MEDP Medpace Holdings | Maintains: Outperform | $200 → $205 | $337.28 | -39.22% | 1 | Jul 20, 2021 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $245 → $250 | $207.51 | +20.48% | 2 | Jul 20, 2021 | |
| ELAN Elanco Animal Health | Upgrades: Outperform | $33 → $38 | $11.63 | +226.74% | 1 | Feb 26, 2021 | |
| FLGT Fulgent Genetics | Downgrades: Underperform | n/a | $18.34 | - | 1 | Jan 8, 2021 | |
| TMO Thermo Fisher | Initiates: Neutral | $341 | $524.05 | -34.93% | 1 | Jan 22, 2020 | |
| INCR InterCure | Maintains: Outperform | $68 → $54 | $1.49 | +3,524.16% | 4 | Nov 14, 2017 |
Rapid7
Jul 10, 2024
Maintains: Equal-Weight
Price Target: $46
Current: $39.36
Upside: +16.87%
Align Technology
Jul 29, 2021
Maintains: Outperform
Price Target: $715 → $732
Current: $211.06
Upside: +246.82%
Charles River Laboratories International
Jul 20, 2021
Maintains: Neutral
Price Target: $352 → $385
Current: $185.77
Upside: +107.25%
IQVIA Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $242 → $265
Current: $197.27
Upside: +34.33%
Medpace Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $200 → $205
Current: $337.28
Upside: -39.22%
ICON Public Limited Company
Jul 20, 2021
Maintains: Outperform
Price Target: $245 → $250
Current: $207.51
Upside: +20.48%
Elanco Animal Health
Feb 26, 2021
Upgrades: Outperform
Price Target: $33 → $38
Current: $11.63
Upside: +226.74%
Fulgent Genetics
Jan 8, 2021
Downgrades: Underperform
Price Target: n/a
Current: $18.34
Upside: -
Thermo Fisher
Jan 22, 2020
Initiates: Neutral
Price Target: $341
Current: $524.05
Upside: -34.93%
InterCure
Nov 14, 2017
Maintains: Outperform
Price Target: $68 → $54
Current: $1.49
Upside: +3,524.16%